Trial abstract · §3
SUSTAIN-7 — results
Primary endpoint, absolute and relative effect where derivable, and harms as reported.
§3Results
§3.1Primary endpoint
Table 3. Primary endpoint as reported.
| Endpoint | Result as reported | Certainty |
|---|---|---|
| Change in glycated haemoglobin from baseline to week 40, semaglutide versus dulaglutide | Difference −0.41 percentage points (95 % CI −0.57 to −0.25) for semaglutide 1.0 mg versus dulaglutide 1.5 mg | High |
| Reproduced from the published report. Where the report states a confidence interval the Institute reproduces it; where it does not, none is constructed. | ||
§3.2Endpoint hierarchy
§3.3Harms as reported
Table 5. Adverse events for Semaglutide from the safety tables the Institute holds for this compound. Where a row names a different trial as its source, the figure is from that trial and not from this one.
| Event | Active, % | Comparator, % | Source trial |
|---|---|---|---|
| Nausea | 44.2 | 17.4 | STEP 1 (68 weeks, 2.4 mg) |
| Diarrhoea | 31.5 | 15.9 | STEP 1 |
| Vomiting | 24.8 | 6.6 | STEP 1 |
| Constipation | 23.4 | 9.5 | STEP 1 |
| Dyspepsia | 9.6 | 3.9 | STEP 1 |
| Abdominal pain | 10.0 | 5.6 | STEP 1 |
| Cholelithiasis | 2.6 | 1.2 | STEP 1 |
| Acute pancreatitis | 0.2 | 0.1 | SELECT (mean 39.8 months) |
Compound Evidence Institute · CEI-TR-0016/3 · https://compoundevidence.com/trials/sustain-7/results/ · retrieved 30 July 2026